Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Lenalidomide
Drug: Obinutuzumab
Drug: Polatuzumab Vedotin
Drug: Rituximab

First Posted Date: 2015-11-09

Last Posted Date: 2023-12-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 114

Registration Number: NCT02600897

Locations: 🇬🇧
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom
🇬🇧
Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom
🇬🇧
Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, United Kingdom

and more 25 locations

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: Lenalidomide
Drug: Vorinostat
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Drug: Rituximab
Drug: Dexamethasone
Drug: Caphosol
Drug: Glutamine
Drug: Pyridoxine
Drug: Enoxaparin
Procedure: Stem Cell Transplant
Drug: Palifermin

First Posted Date: 2015-10-28

Last Posted Date: 2019-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT02589145

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Pembrolizumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-10-20

Last Posted Date: 2021-07-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 310

Registration Number: NCT02579863

GEM-CLARIDEX: Ld vs BiRd

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Clarithromycin
Drug: Dexamethasone

First Posted Date: 2015-10-14

Last Posted Date: 2022-02-01

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 286

Registration Number: NCT02575144

Locations: 🇪🇸
H. del SAS de Jerez, Jerez De La Frontera, Spain
🇪🇸
Hospital Costa del Sol, Marbella, Spain
🇪🇸
Hospital General Universitario Morales Meseguer, Murcia, Spain

and more 23 locations

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: Dinutuximab
Biological: NK Cells
Drug: Lenalidomide

First Posted Date: 2015-10-12

Last Posted Date: 2024-11-05

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Target Recruit Count: 13

Registration Number: NCT02573896

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
C.S Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 8 locations

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Burkitt Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Grade 3a Follicular Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Gray-Zone Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma

Interventions: Biological: Blinatumomab
Drug: Lenalidomide

First Posted Date: 2015-10-06

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT02568553

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 21 locations

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Anaplastic Large Cell Lymphoma, ALK-Negative
Stage II Angioimmunoblastic T-cell Lymphoma
Stage IV Enteropathy-Associated T-Cell Lymphoma
Stage III Angioimmunoblastic T-cell Lymphoma
Stage IV Angioimmunoblastic T-cell Lymphoma
Stage II Enteropathy-Associated T-Cell Lymphoma
Hepatosplenic T-Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Stage III Enteropathy-Associated T-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2015-09-28

Last Posted Date: 2023-12-13

Lead Sponsor: University of Nebraska

Target Recruit Count: 54

Registration Number: NCT02561273

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 5 locations

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Phase 3

Active, not recruiting

Conditions: Plasmacytoma

Interventions: Other: No further treatment
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-09-09

Last Posted Date: 2022-12-23

Lead Sponsor: University College, London

Target Recruit Count: 36

Registration Number: NCT02544308

Locations: 🇬🇧
Freeman Hospital, Newcastle, United Kingdom
🇬🇧
St James University Hospital, Leeds, United Kingdom
🇬🇧
University Hospital Wales, Cardiff, United Kingdom

and more 10 locations

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia, Myeloid

Interventions: Drug: Lenalidomide

First Posted Date: 2015-09-02

Last Posted Date: 2020-01-07

Lead Sponsor: Celgene

Target Recruit Count: 17

Registration Number: NCT02538965

Locations: 🇺🇸
Children's Hospital, Birmingham, Alabama, United States
🇺🇸
Miller Children's Hospital, Long Beach, California, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States

and more 59 locations

Lenalidomide Maintenance in Plasma Cell Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2015-09-02

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 108

Registration Number: NCT02538198

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy